Stim1 silencing after TAC reverted established cardiac
hypertrophy. A, Schematic timeline to study Stim1
silencing effect on TAC-induced heart failure (HF). B, Time-course
of Fractional Shortening (left) and Left Ventricular Internal Diameter (right)
assessed by echocardiography. d=in diastole. Sham (dotted line) vs. TAC
(straight line) animals treated with AAV9.shStim1 (green) or
control (white). C, Cardiac function and volumes assessed by
hemodynamic measurements. Top left, End Diastolic volume (EDV). Top right, End
Systolic Volume (ESV). Bottom left, Ejection Fraction (EF) and bottom right,
representative pressure-volume loops in the four groups of animals.
D, Time-course of Inter Ventricular Septum thickness in
diastole (IVSd) assessed by echocardiography in the four groups of animals. Sham
(dotted line) vs. TAC (straight line) animals treated with
AAV9.shStim1 (green) or control (white). E,
Heart and lung weights at the time of sacrifice. F, Left,
immunofluorescence analysis of left ventricular sections (8μm) using an
antibody against Vinculin (green) and Caveolin1α (red). Nuclei were
stained with DAPI. Images were taken at 20X magnification. Right, quantification
of cardiomyocyte area. N≥6 per groups. * p<0.05, ** p<0.01,
*** p<0.0001.